ARTVNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Artiva Biotherapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$5.89+0.04 (+0.68%)
Close on Oct 19, 2026
- Market cap
- $232.14M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.12 (−2.00%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Artiva Biotherapeutics, Inc. saw revenue fall 100.0% to $0 over fiscal 2025. Free cash flow was -$76.91M.
Revenue
$0
-100.0% vs. a year earlier
Operating income
-$96.15M
TTM Q2 2026
Free cash flow
-$76.91M
TTM Q2 2026
EPS, diluted
-$3.31
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $232.14M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.67
- Dividend yield
- –
- Free cash flow yield
- -33.13%
Fundamentals
- Revenue
- $0
- Net income
- -$90.82M
- EPS, diluted
- -$3.31
- Free cash flow
- -$76.91M
- Book value per share
- $8.82
- Diluted shares
- 39M
Four years at a glance
Fiscal years 2022 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
-$96.15M
Net income
-$90.82M
EPS, diluted
-$3.31
Free cash flow
-$76.91M
Reported periodTrailing twelve months